|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cote ML, Ruterbusch JJ, Olson SH, Lu K and
Ali-Fehmi R: The growing burden of endometrial cancer: A major
racial disparity affecting black women. Cancer Epidemiol Biomarkers
Prev. 24:1407–1415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sheikh MA, Althouse AD, Freese KE, Soisson
S, Edwards RP, Welburn S, Sukumvanich P, Comerci J, Kelley J,
LaPorte RE and Linkov F: USA endometrial cancer projections to
2030: Should we be concerned? Future Oncol. 10:2561–2568. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gey GO: Tissue culture studies of the
proliferative capacity of cervical carcinoma and normal epithelium.
Cancer Res. 12:264–265. 1952.
|
|
6
|
Borrell B: How accurate are cancer cell
lines? Nature. 463:8582010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gillet JP, Calcagno AM, Varma S, Marino M,
Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al:
Redefining the relevance of established cancer cell lines to the
study of mechanisms of clinical Anti-cancer drug resistance. Proc
Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Korch C, Spillman MA, Jackson TA, Jacobsen
BM, Murphy SK, Lessey BA, Jordan VC and Bradford AP: DNA profiling
analysis of endometrial and ovarian cell lines reveals
misidentification, redundancy and contamination. Gynecol Oncol.
127:241–248. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Domcke S, Sinha R, Levine DA, Sander C and
Schultz N: Evaluating cell lines as tumour models by comparison of
genomic profiles. Nat Commun. 4:21262013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Anglesio MS, Wiegand KC, Melnyk N, Chow C,
Salamanca C, Prentice LM, Senz J, Yang W, Spillman MA, Cochrane DR,
et al: Type-specific cell line models for type-specific ovarian
cancer research. PLoS One. 8:e721622013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Beaufort CM, Helmijr JC, Piskorz AM,
Hoogstraat M, Ruigrok-Ritstier K, Besselink N, Murtaza M, van
IJcken WF, Heine AA, Smid M, et al: Ovarian cancer cell line panel
(OCCP): Clinical importance of in vitro morphological subtypes.
PLoS One. 9:e1039882014.PubMed/NCBI
|
|
12
|
Albitar L, Pickett G, Morgan M, Davies S
and Leslie KK: Models representing type I and type II human
endometrial cancers: Ishikawa H and Hec50co cells. Gynecol Oncol.
106:52–64. 2007.PubMed/NCBI
|
|
13
|
Cancer Genome Atlas Research Network;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73.
2013.PubMed/NCBI
|
|
14
|
Murali R, Soslow RA and Weigelt B:
Classification of endometrial carcinoma: More than two types.
Lancet Oncol. 15:e268–e278. 2014.PubMed/NCBI
|
|
15
|
Berger AC, Korkut A, Kanchi RS, Hegde AM,
Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, et al: A
Comprehensive Pan-cancer molecular study of gynecologic and breast
cancers. Cancer Cell. 33:690–705.e9. 2018.PubMed/NCBI
|
|
16
|
Hoadley KA, Yau C, Hinoue T, Wolf DM,
Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, et
al: Cell-of-Origin patterns dominate the molecular classification
of 10,000 tumors from 33 types of cancer. Cell. 173:291–304.e6.
2018.PubMed/NCBI
|
|
17
|
Bairoch A: The cellosaurus, a cell-line
knowledge resource. J Biomol Tech. 29:25–38. 2018.PubMed/NCBI
|
|
18
|
Robin T, Capes-Davis A and Bairoch A:
CLASTR: The cello-saurus STR similarity search tool-A precious help
for cell line authentication. Int J Cancer. 146:1299–1306.
2020.
|
|
19
|
Nishida M, Kasahara K, Kaneko M, Iwasaki H
and Hayashi K: Establishment of a new human endometrial
adenocarcinoma cell line, Ishikawa cells, containing estrogen and
progesterone receptors. Nihon Sanka Fujinka Gakkai Zasshi.
37:1103–1111. 1985.In Japanese. PubMed/NCBI
|
|
20
|
Nishida M, Kasahara K, Oki A, Satoh T,
Arai Y and Kubo T: Establishment of eighteen clones of Ishikawa
cells. Hum Cell. 9:109–116. 1996.PubMed/NCBI
|
|
21
|
Nishida M: The Ishikawa cells from birth
to the present. Hum Cell. 15:104–117. 2002. View Article : Google Scholar
|
|
22
|
Satyaswaroop PG, Zaino RJ and Mortel R:
Human endometrial adenocarcinoma transplanted into nude mice:
Growth regulation by estradiol. Science. 219:58–60. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mo B, Vendrov AE, Palomino WA, DuPont BR,
Apparao KB and Lessey BA: ECC-1 cells: A well-differentiated
Steroid-responsive endometrial cell line with characteristics of
luminal epithelium. Biol Reprod. 75:387–394. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai D, Wolf DM, Litman ES, White MJ and
Leslie KK: Progesterone inhibits human endometrial cancer cell
growth and invasiveness: Down-regulation of cellular adhesion
molecules through progesterone B receptors. Cancer Res. 62:881–886.
2002.PubMed/NCBI
|
|
25
|
Kuramoto H, Nishida M, Morisawa T, Hamano
M, Hata H, Kato Y, Ohno E and Iida T: Establishment and
characterization of human endometrial cancer cell lines. Ann N Y
Acad Sci. 622:402–421. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dai D, Albitar L, Nguyen T, Laidler LL,
Singh M and Leslie KK: A therapeutic model for advanced endometrial
cancer: Systemic progestin in combination with local
adenoviral-mediated progesterone receptor expression. Mol Cancer
Ther. 4:169–175. 2005.PubMed/NCBI
|
|
27
|
Liu Z, Wan G, Heaphy C, Bisoffi M,
Griffith JK and Hu CA: A novel loss-of-function mutation in TP53 in
an endometrial cancer cell line and uterine papillary serous
carcinoma model. Mol Cell Biochem. 297:179–187. 2007. View Article : Google Scholar
|
|
28
|
Richardson GS, Dickersin GR, Atkins L,
MacLaughlin DT, Raam S, Merk LP and Bradley FM: KLE: A cell line
with defective estrogen receptor derived from undifferentiated
endometrial cancer. Gynecol Oncol. 17:213–230. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Way DL, Grosso DS, Davis JR, Surwit EA and
Christian CD: Characterization of a new human endometrial carcinoma
(RL95-2) established in tissue culture. In Vitro. 19:147–158. 1983.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cabrera CM, Cobo F, Nieto A, Cortés JL,
Montes RM, Catalina P and Concha A: Identity tests: Determination
of cell line Cross-contamination. Cytotechnology. 51:45–50. 2006.
View Article : Google Scholar
|
|
31
|
Schroeder A, Mueller O, Stocker S,
Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M
and Ragg T: The RIN: An RNA integrity number for assigning
integrity values to RNA measurements. BMC Mol Biol. 7:32006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Dobin A, Davis CA, Schlesinger F, Drenkow
J, Zaleski C, Jha S, Batut P, Chaisson M and Gingeras TR: STAR:
Ultrafast universal RNA-seq aligner. Bioinformatics. 29:15–21.
2013. View Article : Google Scholar
|
|
33
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A National cancer institute
Workshop on microsatellite instability for cancer detection and
familial predisposition: Development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
34
|
Li H, Handsaker B, Wysoker A, Fennell T,
Ruan J, Homer N, Marth G, Abecasis G and Durbin R; 1000 Genome
Project Data Processing Subgroup: The sequence Alignment/Map format
and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kuilman T, Velds A, Kemper K, Ranzani M,
Bombardelli L, Hoogstraat M, Nevedomskaya E, Xu G, de Ruiter J,
Lolkema MP, et al: CopywriteR: DNA copy number detection from
off-target sequence data. Genome Biol. 16:492015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hoppe MM, Sundar R, Tan DSP and
Jeyasekharan AD: Biomarkers for homologous recombination deficiency
in cancer. J Natl Cancer Inst. 110:704–713. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Satyaswaroop PG: Endometrial Cancer. Human
cell culture. Masters JRW and Palsson B: Springer; Dordrecht: pp.
71–78. 1999
|
|
38
|
van Gool IC, Bosse T and Church DN: POLE
proofreading mutation, immune response and prognosis in endometrial
cancer. Oncoimmunology. 5:e10726752015. View Article : Google Scholar
|
|
39
|
Chen Y, Dey R and Chen L: Crystal
structure of the p53 core domain bound to a full consensus site as
a self-assembled tetramer. Structure. 18:246–256. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Brachova P, Thiel KW and Leslie KK: The
consequence of oncomorphic TP53 mutations in ovarian cancer. Int J
Mol Sci. 14:19257–19275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Brachova P, Mueting SR, Devor EJ and
Leslie KK: Oncomorphic TP53 mutations in gynecologic cancers lose
the normal protein:protein interactions with the microRNA
microprocessing complex. J Cancer Ther. 5:506–516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Brachova P, Mueting SR, Carlson MJ,
Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ and
Leslie KK: TP53 oncomorphic mutations predict resistance to
platinum and Taxane-based standard chemotherapy in patients
diagnosed with advanced serous ovarian carcinoma. Int J Oncol.
46:607–618. 2015. View Article : Google Scholar
|
|
43
|
Walsh CS: Two decades beyond BRCA1/2:
Homologous recombination, hereditary cancer risk and a target for
ovarian cancer therapy. Gynecol Oncol. 137:343–350. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Esteller M, Levine R, Baylin SB, Ellenson
LH and Herman JG: MLH1 promoter hypermethylation is associated with
the microsatellite instability phenotype in sporadic endometrial
carcinomas. Oncogene. 17:2413–2417. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Simpkins SB, Bocker T, Swisher EM, Mutch
DG, Gersell DJ, Kovatich AJ, Palazzo JP, Fishel R and Goodfellow
PJ: MLH1 promoter methylation and gene silencing is the primary
cause of microsatellite instability in sporadic endometrial
cancers. Hum Mol Genet. 8:661–666. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Goodfellow PJ, Buttin BM, Herzog TJ, Rader
JS, Gibb RK, Swisher E, Look K, Walls KC, Fan MY and Mutch DG:
Prevalence of defective DNA mismatch repair and MSH6 mutation in an
unselected series of endometrial cancers. Proc Natl Acad Sci USA.
100:5908–5913. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dubil EA, Tian C, Wang G, Tarney CM,
Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL and
Darcy KM: Racial disparities in molecular subtypes of endometrial
cancer. Gynecol Oncol. 149:106–116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Varughese J, Cocco E, Bellone S, de Leon
M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S
and Santin AD: Uterine serous papillary carcinomas overexpress
human trophoblast-cell-surface marker (Trop-2) and are highly
sensitive to immunotherapy with hRS7, a humanized anti-Trop-2
monoclonal antibody. Cancer. 117:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
English DP, Bellone S, Cocco E, Bortolomai
I, Pecorelli S, Lopez S, Silasi DA, Schwartz PE, Rutherford T and
Santin AD: Oncogenic PIK3CA gene mutations and HER2/neu gene
amplifications determine the sensitivity of uterine serous
carcinoma cell lines to GDC-0980, a selective inhibitor of Class I
PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol.
209:465.e1–e9. 2013. View Article : Google Scholar
|
|
50
|
Bi J, Thiel KW, Litman JM, Zhang Y, Devor
EJ, Newtson AM, Schnieders MJ, Gonzalez Bosquet J and Leslie KK:
Characterization of a TP53 somatic variant of unknown function from
an ovarian cancer patient using organoid culture and computational
modeling. Clin Obstet Gynecol. 63:109–119. 2020. View Article : Google Scholar
|
